NIKKEI 225
38,586.15 -334.11 (-0.86%) HANG SENG
19,376.53 +302.82 (+1.59%) CRUDE OIL
79.27 +0.04 (+0.05%) GOLD FUTURES
2,381.90 -3.60 (-0.15%) DOW
39,869.38 -38.62 (-0.10%) Bitcoin GBP
51,575.00 -619.51 (-1.19%)
MRNA May 2024 107.000 call
| Previous close | 13.80 |
| Open | 13.80 |
| Bid | 25.30 |
| Ask | 26.55 |
| Strike | 107.00 |
| Expiry date | 2024-05-31 |
| Day's range | 13.80 - 13.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 22 |
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
BenzingaPfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
Investor's Business DailyModerna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?
